Posted 4th January 2017 by Jane Williams
Since January 2008, the cost of sequencing a human genome has outpaced Moore’s Law, which states that computing power doubles every two years. It now costs less than $1000 USD to sequence a human genome to a coverage of 30x.
Posted 2nd January 2017 by Jane Williams
Here at the Holst Centre, our technologies have matured in the last few years and our focus has expanded. We concentrate on application driven research, such as wearable health, automotive, the Internet of Things and solar energy.
Posted 30th December 2016 by Jane Williams
Tiffany Scharschmidt spoke to us about her thoughts on the skin microbiome, immune responses and inflammatory skin diseases.
Posted 28th December 2016 by Jane Williams
I love the saying, ‘if you want to go fast, go alone. If you want to go far, go together.’ This is so true in science and research. It takes diverse backgrounds and collaboration to deliver the best products. I find that complex answers are always found in diverse perspectives and collaborations.
Posted 26th December 2016 by Jane Williams
Emmanuel Delamarche is a researcher at IBM Research who presented at our 2nd Microfluidics Congress about his research on precision diagnostics based on modular capillary-driven elements.
Posted 23rd December 2016 by Jane Williams
My research activity focuses on the exploration of new drug delivery technology (categorised into polymer complex/conjugates, nanomedicine, and various types of drug delivery formulations) and the application of validated drug delivery technology to NCE candidates in early/exploratory research stages.
Posted 21st December 2016 by Jane Williams
At the 3rd Microbiome R&D and Business Collaboration Forum: Europe, topics covered the impact of microbiomes on human health and disease, developing therapeutics, and investment into the microbiome. Duc H. Le, the UK Editor-in-Chief of EBioMedicine, summarises some of the presentations that took place.
Posted 19th December 2016 by Jane Williams
Jane Fife has nearly 20 years of expertise in application technology and agricultural biologics. Joining 3Bar Biologics in 2016 as Chief Science Officer, her responsibilities include new product development and leading 3Bar’s long-term R&D portfolio.